Select Page

Since the onset of the COVID-19 pandemic, BioIQ has worked in concert with its national network of lab and medical partners, its Public Health Advisory Board, and leading epidemiologists to develop COVID-19 support solutions for employers, health plans, and government agencies. After announcing the availability of RT-PCR SARS-CoV-2 diagnostic testing in March and quantitative lab-based IgM/IgG antibody testing in April, the company recently unveiled a back-to-work COVID-19 testing program for US employers.

Leveraging BioIQ’s analytics, engagement, monitoring, and testing technology platform, with clinical support from Matrix Medical Network, the COVID-19 testing, testing protocol, assessment, and monitoring solution is designed to protect workers and foster confidence as urgency to bring employees back to work mounts. The consequential offerings offer employers specific guidance on how to do so safely and effectively.

In late March, BioIQ CEO Justin Bellante spoke with CBS46 News about the company’s work to bring COVID-19 testing resources to healthcare workers, essential workforce, and vulnerable populations. Bellante has since appeared on follow-up news broadcasts with the Atlanta CBS affiliate, as well as FOX 5 News and NBC 11 Alive News. BioIQ has also garnered coverage by ABC News and Forbes regarding response to the coronavirus.

The company’s goal is to increase access to testing in a thoughtful way that prioritizes at-risk individuals. “Having a platform surrounding this testing helps you bring it to market and really bring it to people who most need it more effectively,” explained Bellante.

BioIQ has over a decade of experience in health testing programs focused on high-cost conditions such as colorectal cancer (CRC), diabetes, and kidney disease. In an interview with Atlanta INNO, Bellante said the company has had to double down on current client testing needs while also expanding on COVID-19 testing. BioIQ currently works with health plans and employers that cover two-thirds of Americans.

BioIQ emphasizes the importance of not letting traditional preventive care and health screening measures fall through the cracks during the COVID-19 response. The company’s at-home testing solutions for things like CRC offer a viable solution for consumers to continue engaging in these health measures at a time when office visits are limited. And as a follow-up ABC News piece pointed out, although the FDA has yet to approve in-home testing for COVID-19, it could be the future.

In the meantime, BioIQ remains focused on supporting the various testing needs of employers, health plans, and government agencies. “Georgia alone might need tests for at least 20 percent of its population—or enough for about 2.1 million people—in the months ahead,” said Bellante in a recent interview with the Atlanta Journal Constitution.

To learn more about the BioIQ COVID-19 Solution, click here or call 888-818-1594.

Additional Resource: COVID-19 Testing Options Infographic

Share This